Fimasartan
As of the edition of 20 October 2026, Fimasartan is a small molecule: stopped in 2018; acts on AGTR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Small molecule
- Registered trials
- 46, 1 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Hormones; Pregnancy and women's health; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | P30556 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 20 | 20 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 12 | 12 | 0 | 0 |
| Phase 4 | 7 | 2 | 0 | 1 |
| All trials | 46 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boryung Pharmaceutical | Lead sponsor of trials | 2008 to now |